[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100387284":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":36,"centralContacts":41,"locations":46,"responsibleParty":89,"collaborators":92,"id":95,"slug":96,"hasResults":97,"nctId":98,"briefTitle":99,"officialTitle":99,"acronym":10,"eligibilityCriteria":100,"healthyVolunteers":101,"sex":102,"minAge":10,"maxAge":103,"enrollmentInfo":104,"targetDuration":10,"studyType":107,"phases":10,"briefSummary":108,"conditions":109,"keywords":10,"overallStatus":49,"whyStopped":10,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":122},{"fullName":5,"class":6},"Southwest Autism Research & Resource Center","OTHER",[8,12,15,18,21,24,27,30,33],{"label":9,"type":10,"description":11,"interventionNames":10},"ASD (General)",null,"150 children with ASD and unknown MD status",{"label":13,"type":10,"description":14,"interventionNames":10},"ASD (With MD)","50 children with ASD and confirmed MD",{"label":16,"type":10,"description":17,"interventionNames":10},"ASD (No MD)","50 children with ASD and ruled out MD",{"label":19,"type":10,"description":20,"interventionNames":10},"Epilepsy","50 children with epilepsy (primary) and no ASD",{"label":22,"type":10,"description":23,"interventionNames":10},"Brain Tumor","50 children with brain tumor (primary) and no ASD",{"label":25,"type":10,"description":26,"interventionNames":10},"Psychiatric Disorder","50 children with psychiatric disorder (primary) and no ASD, using lithium treatments",{"label":28,"type":10,"description":29,"interventionNames":10},"MD (No ASD)","50 children with MD (primary) and no ASD",{"label":31,"type":10,"description":32,"interventionNames":10},"TD (With ASD Sibling)","50 TD children with a sibling with ASD\u002Fneurodevelopmental delay",{"label":34,"type":10,"description":35,"interventionNames":10},"TD (No ASD Sibling)","50 TD children with no siblings with ASD\u002Fneurodevelopmental delay",[37],{"name":38,"affiliation":39,"role":40},"Richard E Frye, MD, PhD","Autism Discovery & Treatment Foundation","STUDY_DIRECTOR",[42],{"name":38,"role":43,"phone":44,"phoneExt":10,"email":45},"CONTACT","844-ADTFRes","DrFrye@AutismDiscovery.org",[47,71],{"facility":48,"status":49,"city":50,"state":51,"zip":52,"country":53,"countryCode":54,"cosmosGeoPoint":55,"geoPoint":60,"contacts":61},"Southwestern Research and Resource Center","RECRUITING","Phoenix","Arizona","85016","United States","US",{"type":56,"coordinates":57},"Point",[58,59],-112.07404,33.44838,{"lat":59,"lon":58},[62,65,68],{"name":63,"role":43,"phone":64,"phoneExt":10,"email":10},"Christopher J Smith, PhD","(602) 218-8192",{"name":66,"role":43,"phone":67,"phoneExt":10,"email":10},"Sophia Crisler","(480) 582-9467",{"name":69,"role":70,"phone":10,"phoneExt":10,"email":10},"Richard Frye, MD, PhD","PRINCIPAL_INVESTIGATOR",{"facility":72,"status":49,"city":73,"state":74,"zip":75,"country":53,"countryCode":54,"cosmosGeoPoint":76,"geoPoint":80,"contacts":81},"State University of New York, Downstate","Brooklyn","New York","11203",{"type":56,"coordinates":77},[78,79],-73.94958,40.6501,{"lat":79,"lon":78},[82,86],{"name":83,"role":43,"phone":84,"phoneExt":10,"email":85},"Harris Huberman, MD","(718) 270-2272","harris.huberman@downstate.edu",{"name":87,"role":43,"phone":84,"phoneExt":10,"email":88},"Daniel Mishan","autism.research@downstate.edu",{"type":70,"investigatorFullName":90,"investigatorTitle":91,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Richard Frye","Principal Investigator and Sponsor",[93],{"name":94,"class":6},"State University of New York - Downstate Medical Center","100387284","transgenerational-metabolic-immune-biomarkers-of-neurological-and-neurodevelopmental-disorders-100387284",false,"NCT04322734","Transgenerational Metabolic-Immune Biomarkers of Neurological and Neurodevelopmental Disorders","Inclusion Criteria (ASD):\n\n1. ASD, as defined by either a gold standard measure for ASD diagnosis, the Autism Diagnostic Observation Schedule (ADOS); the Autism Diagnostic Interview-Revised (ADI-R); and\u002For a comprehensive assessment that is consistent with ASD, in the opinion of the principal investigator. For those the PI believes a prospective diagnosis of ASD is warranted, a formal diagnostic assessment will be scheduled at screening.\n2. 0 years through 17 years 11 months of age\n\nInclusion Criteria (TD, MD, Epilepsy, Brain Tumor, Psychiatric)\n\n1\\. 0 years to 17 years 11 months of age\n\nExclusion Criteria (All):\n\n1. History of a significant adverse reaction to a prior blood draw\n2. In females of reproductive age, pregnancy or plans to become pregnant\n3. Any other historical event\u002Finformation that may, in the opinion of the PI, be a reason to exclude the child from participation.",true,"ALL","18 Years",{"count":105,"type":106},500,"ESTIMATED","OBSERVATIONAL","The study involves up to 5 visits for a fasting blood draw, behavioral assessments, and\u002For questionnaires. Other samples may be collected when appropriate.\n\nThis study is currently recruiting.\n\nThere is no cost for visits or study-related exams.",[110,111,19,22,25,112],"Autism Spectrum Disorder","Mitochondrial Pathology","Mitochondrial Diseases","2026-04-22",{"date":115,"type":116},"2026-04-23","ACTUAL",{"date":118,"type":116},"2023-12-13",{"date":120,"type":106},"2028-12-31",{"name":5,"class":6},2]